Streetbeat News

LGVNR

Longeveron Inc

Employees

26

Industry

Pharmaceutical Preparation Manufacturing

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Gainers included MSP Recovery (LIFW), Fresh Tracks Therapeutics (FRTX), Bluejay Diagnostics (BJDX), Evaxion Biotech (EVAX), Histogen (HSTO), and TransCode Therapeutics (RNAZ). Losers included Seelos Therapeutics (SEEL), ARS Pharmaceuticals (SPRY), Longeveron Inc. - Subscription Right (LGVNR), Biolase (BIOL), Butterfly Network (BFLY), and Sonoma Pharmaceuticals (SNOA).

Portfolio Pulse from Benzinga Insights

September 20, 2023 | 5:31 pm

Several healthcare stocks experienced significant movement in Tuesday's after-market session. Fresh Tracks Therapeutics, Histogen, Avinger, Longeveron Inc. - Subscription Right, Bluejay Diagnostics, and Exagen saw increases, while Novo Integrated Sciences, ContraFect, HilleVax, IN8bio, Cardio Diagnostics Hldgs, and OKYO Pharma experienced declines.

Portfolio Pulse from Benzinga Insights

September 19, 2023 | 9:31 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Gainers included Avinger, Elutia, Longeveron Inc. - Subscription Right, Applied Therapeutics, Streamline Health Solns, and PAVmed. Losers included UpHealth, Heart Test Laboratories, CareCloud, Histogen, Inhibikase Therapeutics, and MSP Recovery.

Portfolio Pulse from Benzinga Insights

September 19, 2023 | 5:31 pm

During Tuesday's pre-market session, several healthcare stocks experienced significant movements. Longeveron Inc., Avinger, Navidea Biopharmaceutical, Elutia, ABVC BioPharma, and Akili saw increases in their shares, with Longeveron Inc. leading with a 172.7% increase. On the other hand, UpHealth, 60 Degrees, T2 Biosystems, SCWorx, Kinnate Biopharma, and MSP Recovery saw decreases in their shares, with UpHealth experiencing the largest decline of 50%.

Portfolio Pulse from Benzinga Insights

September 19, 2023 | 1:06 pm

In Monday's after-market session, several healthcare stocks saw significant movement. Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares rose by 536.4%, while Avinger (NASDAQ:AVGR) shares increased by 49.42%. Elutia (NASDAQ:ELUT), Aclarion (NASDAQ:ACON), Singular Genomics Sys (NASDAQ:OMIC), and Stereotaxis (AMEX:STXS) also saw increases. On the other hand, Kinnate Biopharma (NASDAQ:KNTE), T2 Biosystems (NASDAQ:TTOO), Redhill Biopharma (NASDAQ:RDHL), Perspective Therapeutics (AMEX:CATX), Tempest Therapeutics (NASDAQ:TPST), and CohBar (NASDAQ:CWBR) saw decreases in their share prices.

Portfolio Pulse from Benzinga Insights

September 18, 2023 | 9:31 pm

During Monday's intraday session, several healthcare stocks experienced significant movements. Gainers included Avinger, Perspective Therapeutics, SCWorx, T2 Biosystems, Mira Pharmaceuticals, and SeqLL, with increases ranging from 33.68% to 79.6%. Losers included Longeveron Inc. - Subscription Right, MSP Recovery, Strata Skin Sciences, Evaxion Biotech, Senti Biosciences, and UpHealth, with decreases ranging from 16.26% to 62.1%.

Portfolio Pulse from Benzinga Insights

September 18, 2023 | 5:31 pm

Several healthcare stocks experienced significant movement in Friday's pre-market session. MSP Recovery, Rezolute, Iovance Biotherapeutics, YS Biopharma, Longeveron Inc. - Subscription Right, and Longeveron saw gains, with MSP Recovery leading with an 83.7% increase. On the other hand, PTC Therapeutics, Scinai Immunotherapeutics, Avalo Therapeutics, ENDRA Life Sciences, Novo Integrated Sciences, and Applied Molecular experienced declines, with PTC Therapeutics leading the losses with a 28.1% decrease.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 1:06 pm

During Thursday's pre-market session, several health care stocks experienced significant movement. Gainers included First Wave BioPharma, Avalo Therapeutics, TransCode Therapeutics, Navidea Biopharmaceutical, Longeveron Inc. - Subscription Right, and Evoke Pharma. Losers included Biolase, Bionomics, Scinai Immunotherapeutics, Impel Pharmaceuticals, ZyVersa Therapeutics, and Petros Pharma.

Portfolio Pulse from Benzinga Insights

September 14, 2023 | 1:06 pm

Several healthcare stocks experienced significant movement in Wednesday's after-market session. Notable gainers included Infinity Pharmaceuticals (INFI), TransCode Therapeutics (RNAZ), Longeveron Inc. - Subscription Right (LGVNR), Scinai Immunotherapeutics (SCNI), Avalo Therapeutics (AVTX), and NanoString Technologies (NSTG). On the other hand, Kiromic BioPharma (KRBP), OKYO Pharma (OKYO), Bionomics (BNOX), Impel Pharmaceuticals (IMPL), Creative Medical Tech (CELZ), and Joint (JYNT) saw declines.

Portfolio Pulse from Benzinga Insights

September 13, 2023 | 9:31 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Avalo Therapeutics, Impel Pharmaceuticals, ZyVersa Therapeutics, Rocket Pharmaceuticals, Novo Integrated Sciences, and Nemaura Medical saw their stocks rise by 54.3%, 51.99%, 40.46%, 36.88%, 32.16%, and 27.14% respectively. On the other hand, Eiger BioPharmaceuticals, Longeveron Inc. - Subscription Right, Mira Pharmaceuticals, Infinity Pharmaceuticals, Creative Medical Tech, and cbdMD saw their stocks fall by 44.6%, 37.16%, 23.73%, 17.56%, 16.4%, and 14.29% respectively.

Portfolio Pulse from Benzinga Insights

September 13, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.